Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126…
<!-- Name:DistributionId Value:8754961 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…